Vaccine testing: Ebola and beyond

Science

Volumn 348, Issue 6230, 2015, Pages 46-47

  Lipsitch, Marc ^h   Eyal, Nir ^a   Halloran, M Elizabeth ^b,c   Hernán, Miguel A ^a   Longini, Ira M ^d   Perencevich, Eli N ^e,f   Grais, Rebecca F ^g  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f Veterans Affairs Iowa City Health Care System   (United States)

^g EPICENTRE   (France)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE;

VACCINE; VIRAL DISEASE;

DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; FOLLOW UP; HUMAN; INCIDENCE; INFECTION RISK; INFORMATION SYSTEM; NATIONAL HEALTH INSURANCE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; STUDY DESIGN; HEMORRHAGIC FEVER, EBOLA; METHODOLOGY; STANDARDS; TREATMENT OUTCOME;

DISEASE OUTBREAKS; EBOLA VACCINES; HEMORRHAGIC FEVER, EBOLA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84928898053     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaa3178     Document Type: Review

References (16)

1. WHO high-level meeting on Ebola vaccines access and financing, 23 October 2014; http://apps.who.int/iris/bitstream/10665/137184/1/WHO-EVD-Meet-EMP-14.2-eng.pdf?ua=1&ua=1.
2. J. H. Giahyue, Liberia begins clinical trial for Ebola vaccines as outbreak ebbs. Reuters, 2 February 2015; www.reuters.com/article/2015/02/02/health-ebola-vaccines-idUSL6N0VC2AE20150202 (2015).
3. A. Maxmen, Why we're still waiting on an Ebola vaccine. Al Jazeera America, 11 March 2015; http://america.aljazeera.com/articles/2015/3/11/why-were-still-waiting-on-anebola-vaccine.html.
4. SAGE Working Group on Vaccination in Acute Humanitarian Emergencies, Vaccination in acute humanitarian emergencies: A framework for decisionmaking (WHO, Geneva, 2013; www.who.int/iris/handle/10665/92462.
5. C. Adebamowo et al., Lancet 384, 1423 (2014).
6. J. P. Matts, J. M. Lachin, Control. Clin. Trials 9, 327 (1988).
7. G. King et al., Lancet 373, 1447 (2009).
8. G. King et al., J. Policy Anal. Manage. 26, 479 (2007).
9. C. C. Iwuji et al., Trials 14, 230 (2013).
10. C. Jennison, B. Turnbull, Group sequential methods with applications to clinical trials, 2000; Chapman-Hall/CRC, Boca Raton, FL.
11. WHO, WHO high-level meeting on Ebola vaccines access and financing: Summary report, 23 October 2014; http://apps.who.int/iris/bitstream/10665/137184/1/WHO-EVD-Meet-EMP-14.2-eng.pdf?ua=1.
12. H. Branswell, Improved Ebola situation in Liberia may complicate vaccine trials, Scientific American; www.scientificamerican.com/article/improved-ebola-situationliberia-may-complicate-vaccine-trials (2014).
13. F. Fleck, A. Lesher, Bull. World Health Organ. 93, 7 (2015).
14. NIAID, PREVAIL Phase 2/3 clinical trial of investigational Ebola vaccines, 2 February 2015; www.niaid.nih.gov/news/QA/Pages/EbolaVaxResultsQA.aspx. (2015).
15. World Health Organization, "Experimental Ebola Vaccines. Situation report, 1 October 2014; www.who.int/mediacentre/news/ebola/01-october-2014/en/" (2014).
16. WHO/MSF/NIPH, Ebola vaccine efficacy trial ready to launch in Guinea, 5 March 2015; www.who.int/mediacentre/news/releases/2015/ebola-vaccine-trial/en/.